Select Your Region
LACTEL® 65:35 DL-PLGE, IV 0.55-0.75 is a premium-quality copolymer with a 65:35 ratio of D,L-Lactide and glycolide with an inherent viscosity of 0.55─0.75 dL/g in HFIP and a degradation time of 4 months maximum.
Physical state: Solid
Form: Granules or pellets
Color: White to yellowish, off-white to light tan
Inherent viscosity (IV) dL/g: 0.55─0.75 (in HFIP)
Degradation time: <4 months
Crystalline Melt Transition (°C): Amorphous
Glass transition temp (°C): 45─50
Solubility (@ 5% w/w): Dichloromethane, tetrahydrofuran, ethyl acetate, chloroform, hexafluoroisopropanol, acetone
Approx. resorption (months): 3─4
Density (g/mL): 1.30
Tensile Strength (psi): 6000─8000
Elongation (%): 3─10
Modulus (psi): 2─4x10⁵
CAS No. 26780-50-7
Primary Chemistry:
Poly(DL-lactide-co-glycolide)
LACTEL® 65:35 DL-PLGE, IV 0.55-0.75 is a cost-effective PLGA-based copolymer characterized by its amorphous properties and controlled degradation period of 4 months. Formulated with a polymer composition of 65 mol % D,L-lactide and 35 mol % glycolide, it is 100% bioresorbable, allowing it to be fully metabolized by the body for exceptional effectiveness. Recommended for controlled drug release systems, such as long-acting injectable formulations for veterinary medicine and human generic drug formulations, LACTEL® 65:35 DL-PLGE, IV 0.55-0.75 is compatible with peptides, proteins, nanoparticles, and microparticles. LACTEL® 65:35 DL-PLGE, IV 0.55-0.75 is non-GMO certified and contains no added preservatives.
Physical state: Solid
Form: Granules or pellets
Color: White to yellowish, off-white to light tan
Inherent viscosity (IV) dL/g: 0.55─0.75 (in HFIP)
Degradation time: <4 months
Crystalline Melt Transition (°C): Amorphous
Glass transition temp (°C): 45─50
Solubility (@ 5% w/w): Dichloromethane, tetrahydrofuran, ethyl acetate, chloroform, hexafluoroisopropanol, acetone
Approx. resorption (months): 3─4
Density (g/mL): 1.30
Tensile Strength (psi): 6000─8000
Elongation (%): 3─10
Modulus (psi): 2─4x10⁵
CAS No. 26780-50-7
Primary Chemistry:
Poly(DL-lactide-co-glycolide)
Human generic drug formulations
Long-acting injectable formulations
Price sensitive applications
veterinary medicine
We’ve detected that you are located in a different region than the region selected on the website. Would you like to change your region?
Current Region: English - United States